Compare Enveric Biosciences Inc (ENVB) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Wendys Co — how do they compare? Enveric Biosciences Inc trades at $1.37 (market cap $5.32M), while Wendys Co trades at $7.7 (market cap $1.42B). The key difference: Wendys Co is far larger — about 266.9× Enveric Biosciences Inc's market cap, and Wendys Co pays a 7.53% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | WEN | |
|---|---|---|
Market Cap | $5.32M | $1.42B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $11.33 |
52-Week Low | $1.28 | $6.17 |
Enterprise Value | $408.82K | $5.23B |
Dividend Yield | — | 7.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
Wendy's (WEN) trades at $7.60, up 2.43% today, with technicals showing a bearish trend but oversold RSI signals. The stock has beaten earnings estimates for three consecutive quarters, though net income margins have declined from 9.37% in 2023 to 6.77% in 2025. Recent news highlights Project Fresh initiatives and meme-driven volatility, with a dividend yield of 7.1% based on the latest payout.
The outlook is mixed: low P/E of 9.66 and high ROE of 120.88% suggest value, but declining profitability and bearish analyst consensus (62.75% hold) signal caution. Key risks include U.S. traffic pressures and cost inflation, while potential catalysts are digital growth and China expansion. Investors face a trade-off between deep value and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
